In our analysis of ACOX2 in NSCLC [80], we identified that ACOX2 may also be a target for MEK inhibitors, which are currently being investigated for their potential utility in the treatment of KRAS-mutated NSCLC [98,99]. Here, KRAS is linked to non-small cell lung carcinoma.